Who Supplies Tofacitinib to India from SOUTH AFRICA

To import finished pharmaceutical formulations containing Tofacitinib into India, the Central Drugs Standard Control Organization (CDSCO) mandates that both the foreign manufacturer and the Indian importer obtain specific approvals. The foreign manufacturer must possess a valid Certificate of Pharmaceutical Product (CoPP) and a Good Manufacturing Practice (GMP) certificate from the country of origin. The Indian importer is required to hold a valid Importer License issued by the Directorate General of Foreign Trade (DGFT). Additionally, the product must be registered with CDSCO, which involves submitting a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA), including comprehensive documentation such as stability data, clinical trial results, and a Certificate of Analysis (CoA). The registration process typically spans several months, depending on the completeness of the submission and the regulatory review process. For formulations under HS Code 30049099, specific requirements include compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The registration ensures that the imported formulations meet India's standards for safety, efficacy, and quality.

Upon arrival in India, finished pharmaceutical formulations containing Tofacitinib are subject to quality testing by CDSCO-approved laboratories. Each batch must be accompanied by a Certificate of Analysis (CoA) from the manufacturer, detailing the product's composition, potency, and compliance with specified standards. Stability data, adhering to International Council for Harmonisation (ICH) guidelines for Zone IV conditions, is also required to demonstrate the product's shelf-life and storage conditions. The formulations must conform to the standards set forth in the Indian Pharmacopoeia. Port inspections by customs drug inspectors are conducted to verify the authenticity and quality of the imported products. If a batch fails to meet the required standards, it may be rejected, leading to potential delays and financial implications for the importer.

Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. Notably, on April 8, 2025, the CDSCO introduced mandatory import registration and licensing requirements for all imported drugs, including finished formulations containing Tofacitinib. This directive aims to prevent the sale of unapproved or illegal medicines in the Indian market. The policy stipulates that both the foreign manufacturer and the Indian importer must obtain the necessary approvals before distribution. Additionally, the Production Linked Incentive (PLI) scheme, introduced in 2020, has impacted the import of finished formulations by providing incentives for domestic manufacturing, thereby encouraging self-reliance and reducing dependency on imports. These policy changes are part of India's broader strategy to enhance the quality and availability of pharmaceuticals within the country.

India imports finished Tofacitinib formulations primarily due to the demand for branded or patented products that are not manufactured domestically. Specific dosage forms, such as extended-release tablets or combination therapies, may not be produced locally, necessitating imports to meet patient needs. While India has a robust pharmaceutical manufacturing sector, certain specialized formulations are still sourced from international markets. The market size for Tofacitinib formulations in India is substantial, with imports totaling $4.0 million across 119 exporters to 67 countries, indicating a significant demand for these products.

The import duty structure for finished pharmaceutical formulations containing Tofacitinib under HS Code 30049099 in India includes a Basic Customs Duty (BCD) of 10%, an Integrated Goods and Services Tax (IGST) of 12%, and a Social Welfare Surcharge (SWS) of 10%. This results in a total landed duty of approximately 17.10%. The BCD is calculated on the Cost, Insurance, and Freight (CIF) value of the goods, while the IGST is applicable on the total of CIF value plus BCD. The SWS is calculated on the BCD amount. These duties are subject to change based on government policies and trade agreements.

India sources finished Tofacitinib formulations from South Africa due to several competitive advantages. South African manufacturers, such as Zydus Healthcare SA (Pty) Ltd., offer formulations that may be patented or not produced domestically, fulfilling specific market needs. The quality of South African pharmaceutical products is generally high, adhering to international standards, which is crucial for the Indian market. While other suppliers like China, Germany, and the United States also export Tofacitinib formulations to India, South Africa's offerings may be more aligned with India's regulatory requirements and market preferences, making it a preferred source.

India imports finished Tofacitinib formulations from South Africa to access specific patented formulations and specialized dosage forms not produced domestically. South African manufacturers offer products that meet international quality standards and align with India's regulatory requirements, ensuring safety and efficacy. These imports fulfill market needs for formulations that are otherwise unavailable within India, thereby enhancing treatment options for patients.

When compared to other origins like China, the European Union, and the United States, South Africa offers competitive advantages in terms of product quality and regulatory compliance. South African pharmaceutical products are known for adhering to international standards, which is crucial for the Indian market. While other countries may offer lower prices, South Africa's consistent quality and alignment with India's regulatory framework make it a preferred source for finished Tofacitinib formulations.

Indian importers face several supply chain risks when sourcing finished Tofacitinib formulations from South Africa. These include potential disruptions due to regulatory changes, currency fluctuations between the South African Rand and the Indian Rupee, and logistical challenges such as shipping delays or port congestion. To mitigate these risks, importers should establish robust contingency plans, maintain diversified supplier relationships, and stay informed about regulatory developments in both countries.